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Weight Loss after Gastric Bypass
Is Associated with a Variant at 15q26.1
Ida J. Hatoum,1,2 Danielle M. Greenawalt,3 Chris Cotsapas,2,4,5 Mark J. Daly,2,4,5 Marc L. Reitman,6,7
and Lee M. Kaplan1,2,*
The amount of weight loss attained after Roux-en-Y gastric bypass (RYGB) surgery follows a wide and normal distribution, and recent
evidence indicates that this weight loss is due to physiological, rather than mechanical, mechanisms. To identify potential genetic fac-
tors associatedwithweight loss after RYGB, we performed a genome-wide association study (GWAS) of 693 individuals undergoing RYGB
and then replicated this analysis in an independent population of 327 individuals undergoing RYGB. We found that a 15q26.1 locus
near ST8SIA2 and SLCO3A1 was significantly associated with weight loss after RYGB. Expression of ST8SIA2 in omental fat of these in-
dividuals at baseline was significantly associated with weight loss after RYGB. Gene expression analysis in RYGB and weight-matched,
sham-operated (WMS) mice revealed that expression of St8sia2 and Slco3a1 was significantly altered in metabolically active tissues in
RYGB-treated compared to WMS mice. These findings provide strong evidence for specific genetic influences on weight loss after
RYGB and underscore the biological nature of the response to RYGB.It is estimated that 66% of adults in the United States are
overweight and that half of these individuals are obese
(MIM 601665).1 Behavioral interventions and pharmaco-
therapies for the treatment of obesity have had limited
long-term success.2–4 In contrast, Roux-en-Y gastric bypass
(RYGB) results in substantial and durable weight loss.5
Individuals who undergo RYGB initially lose an average
of 35%–40% of their baseline weight andmaintain approx-
imately 80% of this weight loss over time.6 Despite its over-
all effectiveness, however, not all people lose the same
amount of weight or obtain the same clinical benefits
from surgery. Indeed, there is a wide and normal distribu-
tion of weight-loss outcomes after RYGB,7,8 and the drivers
of this variation remain largely unknown. Although a vari-
ety of clinical, demographic, psychological, and technical
(surgical) predictors have been identified, these factors
alone and in combination have been able to explain only
a small fraction of the observed variation in weight loss
after surgery.7
Recent evidence indicates that RYGB affects weight loss
through multiple physiological rather than mechanical
mechanisms by altering the regulation of energy expendi-
ture, food intake, food preference, and reward path-
ways.9–11 Weight loss after RYGB thus appears to result
from biological mechanisms, which could be subject to ge-
netic influences. We have recently demonstrated that
genetically related individuals who live separately and
undergo gastric bypass have highly similar weight-loss out-
comes, whereas cohabitating but genetically unrelated in-
dividuals have weight-loss outcomes similar to randomly
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The Amthat genetic factors explain up to 70% of the variability
in weight loss after RYGB.8 Although the specific genetic
contributors are currently unknown, their identification
would enhance our understanding of the mechanisms of
weight loss and help identify those individuals for whom
RYGB is most likely to be effective. Preferential targeting
of surgical therapies to this population could be expected
to improve the overall risk:benefit profile for RYGB.
To identify genetic factors contributing to weight loss af-
ter RYGB, we performed an exploratory genome-wide asso-
ciation study (GWAS) of genetically unrelated individuals
undergoing RYGB (Table S1 in the Supplemental Data
available with this article online). All studies were conduct-
ed in accordance with the ethical standards of the Human
Studies Committee of the Massachusetts General Hospital
(MGH), and written informed consent was obtained for all
participants. From February 2000 until April 2007, we ob-
tained consent from 1,018 (97%) individuals undergoing
RYGB at MGH to collect and analyze tissue samples
removed at the time of surgery. Surgical procedures and
the study population have been described previ-
ously.8,12,13 Intraoperative liver, subcutaneous fat, omental
fat, and stomach tissues were collected in RNAlater (Am-
bion and Applied Biosystems) and stored at 80.
Genomic DNA was extracted from liver samples, and 950
samples were successfully genotyped with the Illumina
HumanHap 650Y BeadChip array at the Gene Expression
Laboratory of Rosetta Inpharmatics. Data were converted
to PLINK format,14 and all genetic analyses were performed
with this software. SNPs with a call rate of <90%, a minor-
allele frequency of <1%, or a Hardy-Weinberg equilibriumachusetts General Hospital, Boston, MA, 02114; 2Department of Medicine,
erck Research Laboratories, Boston, MA 02115; 4Center for Human Genetic
in Medical and Population Genetics, Broad Institute of MIT and Harvard,
ories, Rahway, NJ 07065, USA
itute of Diabetes and Digestive and Kidney Diseases, National Institutes of
y of Human Genetics. All rights reserved.
erican Journal of Human Genetics 92, 827–834, May 2, 2013 827
Figure 1. Manhattan Plot of the Results
of a GWAS of 1,943,373 SNPs and Percent
Weight Loss after RYGB in 693 Individuals
of European Descent
Each SNP is plotted relative to its chromo-
somal location (x axis) and –log10 p value
(left y axis). The horizontal blue line repre-
sents p < 5 3 105.p value of <106 were excluded from analysis, yielding an
initial set of 524,284 SNPs. Using identity-by-descent (IBD)
coefficients for all pairs of individuals, we identified 36
related individuals (relatedness was defined as having an
IBD coefficient R0.125). One person per family was
included for analysis on the basis of completeness of
phenotypic and genetic information. In addition, one
person was removed as a result of having >10% of genetic
information missing. Of the remaining 930 individuals,
806 self-identified as white. To address population struc-
ture not captured through self-identification, we used
EIGENSTRAT15 to calculate principal components of
ancestry and identified 25 outlying samples (greater than
six standard deviations from the mean), resulting in a sam-
ple of 781 participants of confirmed European descent. Of
these 781 samples, 693 had a weight nadir value, were not
onweight-loweringmedications after surgery, did not have
cancer, acute kidney disease, or end-stage renal disease,
and were thus included in the GWAS data set. We imputed
2,199,259 genotypes by using MACH software16 and the
reference set of HapMap CEU (CEPH [Utah residents with
ancestry from northern and western Europe]) SNPs (release
21). After we applied the strict quality-control measures
described above, 1,943,170 SNPs were available for anal-
ysis. Demographic and clinical information was extracted
from a review of electronic medical records. Weight nadir
was defined as the lowest weight at least 10 months after
surgery. Chart-derived nadir weight was validated through
telephone interviews in a subset of participants (n ¼ 306);
there was a 97% correlation between these two sources. We
calculated percent weight loss (%WL) at weight nadir by
subtracting the individual’s weight at nadir from his or
her presurgical weight and then dividing by the individ-
ual’s presurgical weight.
We assessed the association between SNPs and %WL at
the weight nadir after RYGB by using additive models of
quantitative-trait associations. We compared each SNP to
%WL by using additive linear-regression models. We828 The American Journal of Human Genetics 92, 827–834, May 2, 2013observed a genomic control inflation
factor of 1.01, indicating minimal
inflation of test statistics as a
result of population stratification
(Figure S1). SNPs that were within a
250 kb window of each other and
that had an r2 > 0.5 were not consid-
ered independent; only the strongest
associated SNP for each block was
considered for follow up. In thisfirst-stage GWAS, we identified 102 marginally significant
(p< 53 105) SNPs (Figure 1; Table S3), representing 26 in-
dependent loci (pairwise r2 < 0.5).
We carried forward the most significantly associated SNP
in each independent region for validation in an
independent cohort of individuals undergoing RYGB
(Table S2). FromMay 2007 until October 2009, we enrolled
369 individuals undergoing RYGB; all individuals self-
identified as white. Tissue collection methods and clin-
ical-trait extraction were as described for the first-stage
GWAS cohort. DNA was extracted from liver samples, and
genotypes were assessed with a Sequenom MassARRAY at
the Eli and Edythe Broad Institute (Cambridge, MA). Three
hundred twenty-seven individuals had complete genetic
and phenotypic information andwere included in the final
data set. We successfully genotyped 22 SNPs and analyzed
associations with %WL by using additive linear-regression
models. We then conducted meta-analysis on results of the
original and validation cohorts by using fixed-effects
models and inverse variance weights. Using a strict Bonfer-
roni correction based on the SNPs genotyped in the replica-
tion cohort (pBonferroni ¼ 0.0023), we identified the SNP
rs17702901 at 15q26.1 as significantly associated with %
WL after RYGB (preplication ¼ 0.0020). The magnitude of
effect was similar in the GWAS and replication cohorts;
b ¼ 6.70 (95% confidence interval [CI]: 9.7 to 3.7)
and 6.52 (95% CI: 10.7 to 2.4), respectively (Table 1),
and the meta-analyzed magnitude of effect was 6.64
(pmeta-analyzed ¼ 7.4 3 108). Thus, individuals with one
copy of the minor allele of rs17702901 lost, on average,
6.64% less weight after RYGB than those who had two
copies of the major allele at this locus. Although the direc-
tion of the effect (b) for 13 of the 22 SNPs in the replication
cohort was the same as in the GWAS cohort, none of the
other 21 candidate SNPs reached statistical significance in
either the validation cohort or by meta-analysis.
Using pooled data from the two cohorts (n ¼ 1020)
showed that individuals with no copies of the minor allele
Table 1. SNP Association Results between Genotype and Percent Weight Loss after RYGB among Individuals of European Descent in a
GWAS and Replication Cohort
SNP
Closest
Gene MIM
Distance
(bp)a
Reduced
WL Alleleb Chr Position
GWAS Cohort
(N ¼ 693)
Replication Cohort
(N ¼ 327)
Combined
(N ¼ 1020)
b SE3 p Value b SE3 p Value b SE3 p Value
rs10515808 C1QTNF2 ____ 23283 A 5 159753509 4.06 0.75 8.2 3 108 1.17 1.05 0.27 3.08 0.61 4.2 3 107
rs7158359 FOXN3 602628 28219 G 14 88664048 3.03 0.59 3.4 3 107 0.41 0.92 0.65 2.27 0.5 4.6 3 106
rs7129556 AQP11 609914 631 T 11 76977696 2.80 0.55 4.3 3 107 0.60 0.78 0.44 2.07 0.45 3.9 3 106
rs7185923 SALL1 602218 60335 C 16 49802988 2.40 0.49 8.1 3 107 0.63 0.75 0.40 1.89 0.41 3.5 3 106
rs934760 CLASP1 605852 0 G 2 12202672 4.28 0.93 4.6 3 106 0.56 1.37 0.68 2.76 0.77 6.3 3 105
rs1104959 RPS14 130620 79991 G 5 149722429 7.75 1.70 5.8 3 106 0.86 1.95 0.66 4.79 1.28 1.8 3 104
rs9403832 STXBP5 604586 0 T 6 14795969 2.17 0.49 9.8 3 106 0.51 0.72 0.47 1.30 0.4 0.001
rs17702901 ST8SIA2 602546 6728 A 15 90731415 6.70 1.52 1.1 3 105 6.52 2.12 0.002 6.64 1.23 7.4 3 108
rs588217 INTS4 611348 6391 A 11 77261024 2.55 0.58 1.4 3 105 0.59 0.80 0.47 1.87 0.47 7.0 3 105
rs6554217 KDR 191306 32755 C 4 55672161 2.89 0.66 1.5 3 105 1.43 0.99 0.15 1.56 0.55 1.1 3 105
rs9357419 PHACTR1 608723 134845 C 6 12690973 2.95 0.68 1.8 3 105 0.56 0.98 0.56 1.80 0.56 0.001
rs11260025 CLEC4G ____ 12090 T 19 7687753 3.33 0.78 2.2 3 105 1.06 1.07 0.32 1.82 0.63 0.004
rs12803675 OR4C13 ____ 71848 T 11 49858702 3.69 0.87 2.7 3 105 0.37 1.44 0.79 2.80 0.75 1.8 3 104
rs13380914 FBXO15 609093 578813 A 18 69312767 2.50 0.59 2.9 3 105 0.57 0.87 0.51 1.89 0.49 1.2 3 104
rs10518316 SYNPO2 ____ 0 G 4 120241167 2.52 0.60 3.0 3 105 1.37 0.95 0.15 1.41 0.51 2.1 3 105
rs6911409 KCNQ5 607357 0 A 6 73910091 3.71 0.89 3.5 3 105 1.14 1.14 0.32 2.74 0.7 9.7 3 105
rs12659689 RAI14 606586 0 C 5 34836108 1.98 0.48 3.9 3 105 0.11 0.69 0.87 1.39 0.39 4.6 3 104
rs1952291 MIS18BP1 ____ 618149 A 14 45410504 4.32 1.05 4.3 3 105 1.27 1.61 0.42 2.65 0.88 0.003
rs1289666 TTF2 604718 0 T 1 117350312 2.73 0.66 4.3 3 105 0.24 0.97 0.80 1.79 0.55 4.7 3 104
rs11788785 HSD17B3 605573 0 A 9 96111183 2.79 0.68 4.5 3 105 0.68 1.02 0.50 2.14 0.57 1.8 3 104
rs1883264 BIK 603392 0 G 22 41834344 2.85 0.70 4.6 3 105 0.76 1.04 0.46 2.21 0.58 1.7 3 104
rs12696123 MIR135A2 ____ 66339 C 3 163099074 2.36 0.58 4.7 3 105 0.24 0.84 0.77 1.52 0.47 1.3 3 104
aAbsolute value of the distance from the start or stop site of the closest gene. A distance of 0 indicates that the SNP is located within the gene.
bAllele associated with decreased weight loss.(A) of rs17702901 (n ¼ 967) lost an average of 38.7% of
their body weight, whereas individuals carrying a single
copy of this variant (n ¼ 52) lost an average of 33.5%
(Figure 2A). The sole homozygous AA individual had a
%WL of 28.8%. The rs17702901 genotype explained
2.8% of the variance in %WL. This SNP was not associated
with baseline BMI in this population (p ¼ 0.33) or with
BMI in the GIANT17 consortium analysis (p ¼ 0.89). To
examine the predictive utility of rs17702901 for discrimi-
nating individuals, we categorized individuals into those
who lost more than 30% of their baseline weight (n ¼
849) and those who lost 30% or less of their baseline
weight (n ¼ 171) at weight nadir, and we conducted logis-
tic regression analyses by using SAS statistical software (SAS
Institute). Individuals with at least one copy of the minor
allele were 2.54 times more likely to experience weight
loss % 30% than individuals with no copies of this allele
(p < 0.0001). No individuals with the minor allele lost
more than 50% of his or her initial weight (corresponding
to the upper 10% of the weight loss distribution;The AmFigure 2B). We next tested the predictive ability of this
SNP by adding it to a clinical model for predicting weight
loss after RYGB. Logistic regression models were con-
structed, and the area under the receiver operating charac-
teristic curve (AUROC) before and after the addition of
rs17702901 was assessed.18 Clinical variables included
age at the time of surgery, sex, preoperative BMI measured
by a nurse 0–7 days before surgery, and type 2 diabetes mel-
litus status (T2D; MIM 125853), determined by a review of
the medical record (Table S2 and Figure S2). After multivar-
iable adjustment, rs17702901 remained significant (Table
S3). In the clinical model alone, the AUROC was 0.620;
with the addition of rs17702901, the AUROC increased
slightly to 0.633 (p ¼ 0.36). These analyses indicate that
rs17702901 is associated with decreased weight loss, inde-
pendent of current clinical predictors, and highlight the
potential predictive utility of this marker.
We analyzed expression of the two genes closest to
rs17702901—ST8SIA2 (MIM 602546), located ~6.7 kilo-
bases (kb) downstream of rs17702901, and SLCO3A1erican Journal of Human Genetics 92, 827–834, May 2, 2013 829
Figure 2. Weight Loss after RYGB by rs17702901 Genotype Sta-
tus
(A) Percent weight loss in individuals after Roux-en-Y gastric
bypass by rs17702901 genotype. Error bars denote the minimum
and maximum value by group.
(B) Distribution of percent weight loss in individuals after Roux-
en-Y gastric bypass by rs17702901 status. Grey bars indicate indi-
viduals with no rs17702901 minor alleles; purple bars indicate
individuals with one copy of the minor allele; and the red bar in-
dicates the single individual with two copies of the minor allele.(MIM 612435), located ~223 kb upstream of this SNP—in
liver, subcutaneous fat, and omental fat obtained from par-
ticipants in the first-stage GWAS. A detailed description of
the sample processing, normalization, and data-cleaning
methods has been provided previously.12 After adjustment
for age, sex, diabetes, and preoperative BMI in linear-
regression models, increased expression of ST8SIA2 in
omental fat was significantly associated with %WL (p ¼
0.008). This relationship persisted after adjustment for
rs17702901 genotype (pST8SIA2 ¼ 0.008; prs17702901 ¼
0.007). Neither expression of ST8SIA2 in liver or subcu-
taneous fat nor expression of SLCO3A1 in any of these
three tissues was significantly associated with %WL. We
next examined whether genotype at the rs17702901 locus
was associated with the expression level of any of ~44,000
transcripts in liver, omental fat, and subcutaneous fat.12
We determined the association between rs17702901 geno-
type and gene expression in liver, subcutaneous fat, and
omental fat by using Kruskal-Wallace tests and adjusting
for the effect of surgery year, age, race, and sex by using a830 The American Journal of Human Genetics 92, 827–834, May 2, 2principal-components analysis.12 Using this approach,
we detected no multiple-test-corrected, significant associa-
tions (expression quantitative trait loci [eQTL]) between
rs17702901 and preoperative expression of any tran-
scripts, including ST8SIA2 and SLCO3A1 (Table S4).
We examined the effect of RYGB on expression of the or-
thologs of ST8SIA2 and SLCO3A1 in amouse gastric-bypass
model that closely mimics the procedure in humans.19,20
All experiments in mice were performed in compliance
with and were approved by the Institutional Animal Care
and Use Committee of the Massachusetts General Hospi-
tal. At 12 weeks of age, male, diet-induced-obese C57BL/
6 mice that had been on a high-fat diet since weaning
(Jackson Laboratories, Bar Harbor, ME) were randomized
to RYGB or sham operation with food restriction to match
the weights of the RYGB mice weekly. The comparison of
RYGB to weight-matched, sham-operated (WMS) mice al-
lows for the identification of effects that are specific to sur-
gery and independent of the effects of weight loss alone.
Surgical procedures and postoperative care have been
described previously.20 Ten weeks after surgery, animals
were euthanized by carbon dioxide inhalation followed
by cervical dislocation, and tissues were harvested immedi-
ately (Figure S3), flash frozen, and stored at 80C until
further processing. Total RNA was extracted with the Su-
perScript III First-Strand Synthesis System for RT-PCR kit
(Invitrogen) according to the manufacturer’s instructions.
One microgram of total RNA was used as a template for
cDNA synthesis with the TaqMan Gene Expression Master
Mix kit (Applied Biosciences). The relative expression level
was determined by qPCR with preoptimized, gene-specific
primer probe sets purchased from Applied Biosciences (cat-
alog number 4331182) for Slco3a1 and St8sia2, and expres-
sion was analyzed with a CFX96 Real-Time PCR Detection
System (BioRad). Data were normalized to actin, and one-
way ANOVAs were calculated for each transcript. Expres-
sion of Sta8sia2, the mouse ortholog of the gene closest
to rs17702901, was significantly lower in the epididymal
fat and liver of RYGB-treated than WMS mice
(Figure 3A). In addition, expression of Slco3a1 in the
mid-jejunum (alimentary limb) was significantly greater
in the RYGB group than in WMS controls (Figure 3B).
We next analyzed the results in humans by using a gene-
based association test that integrates SNP associations with
linkage-disequilibrium patterns within each gene,21 and
identified a marginally significant association (p ¼ 8.0 3
107) with aquaporin 11 (AQP11 [MIM 609914]; Table
S5). Although there were 27 SNPs with a p value < 0.001
in this region, there was no statistically significant associa-
tion between the region’s top SNP, rs7129556, and%WL in
the replication cohort (Figure 4A). Because only one SNP
per independent locus was carried forward, the other 26
SNPs in this region were not genotyped in the replication
cohort. We detected no genome-wide, multiple-test-cor-
rected, significant associations between rs7129556 and
the expression of any transcripts in humans, but this
SNP was marginally associated with expression of AQP11013
Figure 3. Comparative Expression of St8sia2 and Slco3a1 in
RYGB-Treated and Sham-Operated, Weight-Matched Mice
Grey bars denote the sham-operated, weight-matched (WMS)
group, and blue bars indicate the RYGB group. Error bars
denote the standard error of the mean. *p < 0.05, **p < 0.01,
and ***p < 0.001.itself (pomental ¼ 9.7 3 105, pliver ¼ 1.6 3 104; Table S6).
AQP11 expression in humans did not correlate with %WL
in any tissue. We assessed gene expression of Aqp11 and
Clns1a, the next closest gene to rs7129557, in the mouse
models of RYGB as described above by using primer probe
sets purchased from Applied Biosciences (catalog number
4331182) for Aqp11 and Clns1a. In the mouse models,
Aqp11 expression in the alimentary limb and liver was
significantly lower after RYGB than in WMS mice
(Figure 4B). In contrast, expression of Clns1a was not
significantly changed after RYGB (Figure 4C).
Because the physiological mechanisms underlying pre-
disposition to obesity and weight loss after RYGB could
be related, we assessed whether previously reported and
validated BMI-associated loci17 were also associated with
weight loss after RYGB in humans. None of the 32 previ-
ously reported BMI-associated loci were associated with
weight loss after surgery in the GWAS or replication co-
horts (Table S7). Furthermore, none of the SNPs identified
in the GWAS stage (Table 1) were significantly associated
with BMI in the GIANTconsortium17 in the GWAS or repli-The Amcation cohorts (Table S8) after multiple-test correction,
although rs3810291 and rs11847697 demonstrated mar-
ginal significance (uncorrected p values at both loci
0.01). In addition, deep sequencing of the MC4R (MIM
155541) locus showed no evidence of an association be-
tween variants in this gene and weight loss after RYGB.20
Finally, 28 T2D-associated loci were similarly not associ-
ated with weight loss after RYGB in the GWAS cohort (Ta-
ble S9). None of the BMI or diabetes-associated SNPs were
in linkage disequilibrium with rs17702901. Taken
together, these findings suggest that the mechanisms of
weight loss, particularly weight loss achieved with RYGB,
could be distinct from the mechanisms associated with
sustained elevated body weight.
In the current study, we have identified and validated a
single genetic locus, near ST8SIA2 and SLCO3A1, that is
significantly associated with weight loss after RYGB.
Expression of ST8SIA2 in human omental tissue was
associated with weight loss, further supporting the poten-
tial physiological relevance of this locus. These findings
underscore the physiological mechanisms of action of
RYGB and highlight the importance of biological,
including genetic, factors in determining outcomes after
this bariatric procedure.
ST8SIA2 encodes a sialyltransferase that catalyzes the
transfer of polysialic acid to neural cell adhesion molecule
1 (NCAM1), resulting in posttranslational modification of
NCAM1 and influencing brain development.22 SNPs near
ST8SIA2 are associated with autism (MIM 209850), bipolar
disorder (MIM 125480), and schizophrenia (MIM
181500).23–26 Notably, mutation of St8sia2, the mouse or-
tholog of this gene, has been associated with obesity in a
congenic mouse model, although the mechanisms by
which this gene might influence body fat are unclear.27
SLCO3A1 encodes organic anion transporting polypeptide,
subtype D (OATP-D), which transports organic solutes,
including certain drugs and xenobiotics.28 OATP-D also in-
fluences the cellular uptake of prostaglandins, which could
influence hormone regulation and muscle contraction af-
ter RYGB.28 Other members of the OATP family have
been shown to be associated with bile acid transport,29
which is altered after RYGB,30,31 and OATP-D itself has
recently been postulated to play a role in this process as
well.32 We also found that SNPs in and near AQP11 are
associated with WL after RYGB and that Aqp11 expression
is downregulated after RYGB in mice in aWL-independent
manner.AQP11 encodes amember of the aquaporin family
of membrane transporters.33 It has low sequence similarity
to most family members, and its physiological function is
unknown. Recently, however, Aqp11 has been shown to
play a role in kidney development in mice.34,35 Based on
the totality of the evidence, we hypothesize that ST8SIA2,
SLCO3A1, and AQP11 might play a role in the widespread
metabolic changes seen after RYGB and similar bariatric
operations.
Despite these findings, it is important to note the limita-
tions of this study. First, with only 693 participants, it iserican Journal of Human Genetics 92, 827–834, May 2, 2013 831
Figure 4. Analysis of the AQP11 Region
(A) Regional association plot of the AQP11
locus. Each SNP is plotted as a diamond on
the basis of its chromosomal location
(x axis) and log10 p value (left y axis).
Recombination rates are plotted in blue
(right y axis). The large red diamond repre-
sents the region’s top SNP (rs7129556)
from the GWAS, and the large blue dia-
mond represents the p value for that SNP
in the replication cohort. White diamonds
are not in significant linkage disequilib-
rium (LD) with rs7129556, whereas red, or-
ange, and yellow diamonds are in strong
(r2R 0.8), moderate (0.5% r2 < 0.8), and
weak (0.2 % r2 < 0.5) LD, respectively.
Expression of Aqp11 (B) and Clns1a (C) is
shown. Grey bars denote the WMS group,
and blue bars denote the RYGB group. Er-
ror bars denote the standard error of the
mean. *p < 0.05, **p < 0.01, and ***p <
0.001.almost certainly underpowered to detect most genetic
effects. Theability todetect evena single locus,however, un-
derscores the contribution of genetic factors to surgical out-
comes8 and suggests a strong likelihood of identifying addi-
tional genetic contributors to weight loss after RYGB.
Second, because this study included only individuals of Eu-
ropeandescent,wedonot knowwhether these samegenetic
factors are relevant to other populations. As genetic infor-
mation from additional cohorts who have undergone
RYGB becomes available, we will be able to compare and/
or combine the results from these studies to address each
of these limitations. Finally, the mechanisms through
which the identified loci influence postoperative weight
loss are unclear. Functional assessment of thepotential roles
of the genes identified through this association studywill be
necessary ifwe are to address this important question. Itwill
also be necessary to determine whether the identified ge-
netic factorspredictweight loss achieved throughdiet, phar-
maceuticals, or other surgical procedures or whether these
genetic factors are specific to RYGB-induced weight loss.
In conclusion, we have identified a genetic locus that is
reproducibly associated with weight loss after RYGB. This
study provides evidence for the use of genomics to identify
response to surgical procedures (surgicogenomics). Com-
parison of genetic predictors identified for RYGB with
those identified for other weight-loss procedures could
provide insight into their shared and distinct mechanisms832 The American Journal of Human Genetics 92, 827–834, May 2, 2013of action. The gene(s) responsible for
the correlation between rs17709201
and postoperative weight loss should
provide additional insight into the
mechanisms of action of RYGB
and elucidate potential targets for
obesity therapies. Given the wide
distribution of outcomes after RYGB,
including in individuals carrying thers17702901 minor allele, we cannot recommend that
rs17702901 allele status, in isolation, be used as an exclu-
sion criterion for surgical therapy. Identification of
additional genetic contributors to weight loss, comorbidity
resolution, and adverse outcomes after RYGB and their
incorporation into composite models that include vali-
dated clinical predictors of outcome could help to more
precisely identify those individuals who will obtain the
greatest benefit from RYGB and other types of weight-
loss surgery. Furthermore, future identification of predic-
tors of long-term weight stabilization would provide
important information that would complement the identi-
fied predictors of initial weight loss. Together, these
approaches could facilitate identification of individuals
who would benefit most from RYGB and thereby improve
the overall utility of this highly effective yet invasive
treatment.
Supplemental Data
The Supplemental Data include three figures and nine tables and
can be found with this article online at http://www.cell.com/
AJHG/.
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